Affiliate & advertising disclosure
Last updated: June 2026
The GLP-1 Verdict is a reader-supported, independent comparison publication. When you click through to a provider and sign up, we may earn a commission — at no additional cost to you. That commission funds our research, the ongoing re-verification of provider pricing, and keeping this site free to read. Here is exactly how that works, in plain terms.
Partner vs. editorial review
We have affiliate partnerships with some, but not all, of the providers we cover. Every provider on the site carries a label:
- Partner — we earn a commission if you sign up through our link, and we may give them promotional emphasis (for example, the top-of-page spotlight or a highlighted card). These are always labeled.
- Editorial review — we have no commercial relationship with this provider. We review and rank them anyway, because a comparison that only covers paying partners isn't worth your trust.
The score is independent. Emphasis is labeled.
Our Verdict Score is editorial judgment formed under the same six weighted factors for every provider — see our methodology. A commercial relationship never adds points to a score, and a provider that performs poorly is ranked accordingly whether they pay us or not. What a partnership can influence is promotional emphasis — spotlights, featured cards, how often we write about a provider — and we label that emphasis wherever it appears. Score is independent; placement emphasis is disclosed.
Who we are
The GLP-1 Verdict is operated by an independent publisher. We are not a medical provider, pharmacy, or telehealth company, and we are not affiliated with any provider or drug manufacturer beyond standard affiliate agreements. We do not cover every provider in the market; the ones we review reflect our editorial priorities and reader interest.
Not medical advice
Choosing a GLP-1 provider is a personal health decision, and our rankings are a research starting point — not medical advice. Compounded GLP-1 medications are not FDA-approved finished drug products. Always consult a licensed clinician before starting any medication. Pricing, availability and regulatory status change constantly — confirm current details on the provider's own site. See our medical disclaimer.
Trademark notice
Wegovy®, Ozempic® and Rybelsus® are trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. We use these names only to identify the medications discussed. Their use does not imply endorsement or affiliation, and The GLP-1 Verdict is not affiliated with Novo Nordisk, Eli Lilly, or any other manufacturer.
Questions
Reach us via the details on our about page.